The Annual General Meeting of Active Biotech was held on May 20, 2026. The following main resolutions were passed.
In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid for the financial year 2025, and that the Company's accumulated loss shall be carried forward.
The members of the Board and the CEO were discharged from liability with respect to their management of the Company for 2025.
In accordance with the Election Committee's proposal, the Board members Michael Shalmi, Peter Thelin and Aleksandar Danilovski were re-elected. Michael Shalmi was re-elected Chairman of the Board and Öhrlings PricewaterhouseCoopers AB was re-elected as auditor.
In accordance with the Election Committee's proposal, the Meeting resolved that fees payable to the Board shall unchanged amount to SEK 500,000 to the Chairman of the Board and SEK 200,000 to each of the other Board members who are not employed by the Company. Furthermore, the Meeting resolved that a member of the Board who performs work for the Company outside the scope of the Board work may also receive remuneration on market terms for such work performed.
The Meeting approved the Board's remuneration report.
The Meeting resolved, in accordance with the Election Committee's proposal, that the Election Committee shall be composed of the Chairman of the Board and one member appointed by each of the three largest shareholders of the Company based on the ownership structure at the end of September 2026.
In accordance with the Board's proposal, the Meeting resolved on a reverse split of shares, entailing that one hundred (100) existing shares are consolidated into one (1) share (reverse split 1:100). Following the reverse share split, the number of shares and votes in the Company will amount to 26,360,671. The quotient value will amount to approximately SEK 0.516399. The Board of Directors is authorised to determine the record date for the reverse share split and to otherwise take such measures as may be required for the implementation of the reverse share split. In connection with the determination of the record date for the reverse share split, the Board of Directors will publish the timetable for the reverse share split as well as further information regarding the procedure for the reverse share split.
To enable the reverse share split, the Meeting also resolved on, in accordance with the Board's proposal, an amendment of the Articles of Association, whereby the limits of on the number of shares are amended to not less than 20,000,000 shares and not more than 80,000,000 shares.
In accordance with the Board's proposal, the Meeting finally resolved to authorize the Board to, for a period that does not extend past the date of the next Annual General Meeting, with or without pre-emptive rights for the shareholders, resolve on the issue of new shares and/or convertibles, corresponding to not more than 30 percent of the total number of shares in the Company after utilization of the authorization.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies have been initiated. Laquinimod is in development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation has been performed to support phase II development together with a partner. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.
